MainMarket in brief


Sberbank acquired 45% of Eapteka by investing $76 million

February 11, 2021, 18:00 (UTC+3)|

Sberbank and R-Pharm Group announced that the joint investment deal in Eapteka was completed. They acquired 45% of the online pharmaceutical retailer each. The remaining 10% was retained by the founder and CEO of Sber Eapteka, Anton Buzdalin.

Sberbank’s investment in the deal amounted to 5.7 billion rubles (equivalent to $76 million) The money will be used to “improve the quality of service and expand activities into the regions of Russia”. In 2021, it is planned to launch the service in 76 cities of the country. In many of these cities the purchase of drugs with delivery will become available for the first time.

The joint investment in the company was first announced in October 2020. Since November 2020, Eapteka has been operating as part of the Sberbank ecosystem and has been developing under the Sber Eapteka brand.


Lev Khasis, First Deputy Chairman of the Executive Board of SberBank

Anton Buzdalin, founder and CEO of Sber Eapteka 


Interested In The Russian IT Market? Subscribe!

By clicking the button you agree to Privacy Policy

Unless otherwise stated, the content is available under Creative Commons BY 4.0 license

Supported by the Moscow Government